Geode Capital Management LLC Has $126.03 Million Stock Position in TG Therapeutics, Inc. $TGTX

Geode Capital Management LLC lifted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 6.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,490,457 shares of the biopharmaceutical company’s stock after acquiring an additional 207,890 shares during the period. Geode Capital Management LLC owned approximately 2.20% of TG Therapeutics worth $126,033,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. CWM LLC increased its holdings in TG Therapeutics by 16.2% during the 1st quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 290 shares in the last quarter. Victory Capital Management Inc. boosted its position in shares of TG Therapeutics by 70.4% during the first quarter. Victory Capital Management Inc. now owns 92,081 shares of the biopharmaceutical company’s stock valued at $3,631,000 after buying an additional 38,047 shares during the last quarter. Kestra Private Wealth Services LLC bought a new stake in TG Therapeutics during the first quarter worth $221,000. Teachers Retirement System of The State of Kentucky grew its holdings in TG Therapeutics by 71.2% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 76,115 shares of the biopharmaceutical company’s stock worth $3,001,000 after buying an additional 31,665 shares in the last quarter. Finally, Choreo LLC raised its position in TG Therapeutics by 7.6% in the 1st quarter. Choreo LLC now owns 8,547 shares of the biopharmaceutical company’s stock valued at $337,000 after buying an additional 602 shares during the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $30.33 on Thursday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The firm has a market cap of $4.82 billion, a price-to-earnings ratio of 81.97 and a beta of 1.96. TG Therapeutics, Inc. has a 52 week low of $25.28 and a 52 week high of $46.48. The firm’s 50-day simple moving average is $33.83 and its two-hundred day simple moving average is $34.02.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $2.19. The company had revenue of $161.71 million during the quarter, compared to analyst estimates of $152.12 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. TG Therapeutics’s quarterly revenue was up 92.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.02 EPS. TG Therapeutics has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on TGTX. Wall Street Zen upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. JPMorgan Chase & Co. upped their price objective on shares of TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. HC Wainwright began coverage on shares of TG Therapeutics in a research report on Monday, October 6th. They set a “buy” rating and a $60.00 target price on the stock. B. Riley upgraded TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $50.25.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the business’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total value of $672,268.48. Following the sale, the director directly owned 94,061 shares in the company, valued at $3,032,526.64. The trade was a 18.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 10.64% of the stock is owned by corporate insiders.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.